ReviewInternational journal of clinical oncology2026
Nationwide trends in surgery selection and minimally invasive surgery for cervical cancer with preoperative T1B1/T1B2 disease in Japan.
Review in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Laparoscopic Approach to Cervical Cancer trial and FIGO 2018 staging revision have significantly influenced the management of cervical cancer; however, their impact on treatment selection in Japan remains unclear.
methodsWe analyzed 16,054 patients with squamous cell carcinoma, usual-type adenocarcinoma, or adenosquamous carcinoma registered in the nationwide Japan Society of Obstetrics and Gynecology registry (2015-2022) with FIGO 2018 stage IB1, IB2, or IIIC1 corresponding to T1B1 or T1B2. Temporal changes in surgery selection and minimally invasive surgery (MIS) utilization by pelvic lymph node metastasis (LNM) and local T stage were evaluated.
resultsPelvic LNM was associated with reduced surgery selection during 2015-2018 (OR 0.38, 95% CI 0.30-0.48), with no significant change after 2018 (interaction OR 0.76, 95% CI 0.56-1.02). Among surgical patients, MIS utilization did not differ by pelvic LNM status before 2018; however, MIS avoidance in LNM-positive cases became evident after 2018 (interaction OR 0.41, 95% CI 0.26-0.64). T1B2 exhibited lower MIS utilization than T1B1 (OR 0.62, 95% CI 0.54-0.71), with a greater decline post-2018 (interaction OR 0.44, 95% CI 0.36-0.54). In an exploratory survival analysis, MIS utilization was not significantly associated with overall survival after adjustment (HR 0.96, 95% CI 0.89-1.04), although this finding should be interpreted cautiously.
conclusionsIn Japan, the trend of avoiding surgery for pelvic LNM-positive disease existed before the FIGO 2018. However, MIS avoidance became evident after 2018, particularly in pelvic LNM-positive disease and T1B2 tumors.
Indexed as
Identifiers
42286379What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.